Strategies for the enhancement of anti-cancer effect of phosphodiesterase type 5 inhibitors using drug binding fusion proteins
Drug repurposing is a rapidly growing for the development of new therapeutic agents. Among them, phosphodiesterase-5 (PDE5) inhibitors, which show excellent effects as a treatment for erectile dysfunction, have been continuously reported for their potential as anti-cancer agents. It is necessary to...
Saved in:
| Published in | Biotechnology and bioprocess engineering Vol. 29; no. 1; pp. 85 - 96 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Seoul
The Korean Society for Biotechnology and Bioengineering
01.02.2024
Springer Nature B.V 한국생물공학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1226-8372 1976-3816 |
| DOI | 10.1007/s12257-024-00014-8 |
Cover
| Abstract | Drug repurposing is a rapidly growing for the development of new therapeutic agents. Among them, phosphodiesterase-5 (PDE5) inhibitors, which show excellent effects as a treatment for erectile dysfunction, have been continuously reported for their potential as anti-cancer agents. It is necessary to apply targeted delivery systems to enhance the efficacy of the PDE5 inhibitors (PDE5i) as anti-cancer drugs. In this study, PDE5 inhibitor-binding domain (PBD) was developed to incorporate PDE5i into antibody using biological affinity binding without any chemical modifications. The PBD spontaneously bound with PDE5i, resulting in the formation of PBD/PDE5i complex. We also constructed a recombinant fusion protein composed of an anti-HER2 scFv and PBD (HER2 scFv-PBD) to deliver the PDE5i for the treatment of HER2 positive cancer cells. HER2 scFv-PBD could deliver the PDE5i into HER2-positive cancer cells and enhanced anti-cancer effect of the PDE5i. We have demonstrated the potential of tumor-directed PDE5 inhibition as a novel form of targeted therapy using drug binding fusion proteins. |
|---|---|
| AbstractList | Drug repurposing is a rapidly growing for the development of new therapeutic agents. Among them, phosphodiesterase-5 (PDE5) inhibitors, which show excellent eff ects as a treatment for erectile dysfunction, have been continuously reported for their potential as anti-cancer agents. It is necessary to apply targeted delivery systems to enhance the effi cacy of the PDE5 inhibitors (PDE5i) as anti-cancer drugs. In this study, PDE5 inhibitor-binding domain (PBD) was developed to incorporate PDE5i into antibody using biological affi nity binding without any chemical modifi cations. The PBD spontaneously bound with PDE5i, resulting in the formation of PBD/PDE5i complex. We also constructed a recombinant fusion protein composed of an anti-HER2 scFv and PBD (HER2 scFv-PBD) to deliver the PDE5i for the treatment of HER2 positive cancer cells. HER2 scFv-PBD could deliver the PDE5i into HER2-positive cancer cells and enhanced anti-cancer eff ect of the PDE5i. We have demonstrated the potential of tumor-directed PDE5 inhibition as a novel form of targeted therapy using drug binding fusion proteins. KCI Citation Count: 0 Drug repurposing is a rapidly growing for the development of new therapeutic agents. Among them, phosphodiesterase-5 (PDE5) inhibitors, which show excellent effects as a treatment for erectile dysfunction, have been continuously reported for their potential as anti-cancer agents. It is necessary to apply targeted delivery systems to enhance the efficacy of the PDE5 inhibitors (PDE5i) as anti-cancer drugs. In this study, PDE5 inhibitor-binding domain (PBD) was developed to incorporate PDE5i into antibody using biological affinity binding without any chemical modifications. The PBD spontaneously bound with PDE5i, resulting in the formation of PBD/PDE5i complex. We also constructed a recombinant fusion protein composed of an anti-HER2 scFv and PBD (HER2 scFv-PBD) to deliver the PDE5i for the treatment of HER2 positive cancer cells. HER2 scFv-PBD could deliver the PDE5i into HER2-positive cancer cells and enhanced anti-cancer effect of the PDE5i. We have demonstrated the potential of tumor-directed PDE5 inhibition as a novel form of targeted therapy using drug binding fusion proteins. |
| Author | Keum, Chang Yeop Lim, Kwang Suk Kim, Hongbin Lim, Su Yeon |
| Author_xml | – sequence: 1 givenname: Hongbin surname: Kim fullname: Kim, Hongbin organization: Department of Smart Health Science and Technology, Kangwon National University – sequence: 2 givenname: Chang Yeop surname: Keum fullname: Keum, Chang Yeop organization: Department of Smart Health Science and Technology, Kangwon National University – sequence: 3 givenname: Su Yeon surname: Lim fullname: Lim, Su Yeon organization: Department of Smart Health Science and Technology, Kangwon National University – sequence: 4 givenname: Kwang Suk surname: Lim fullname: Lim, Kwang Suk email: kslim@kangwon.ac.kr organization: Department of Smart Health Science and Technology, Kangwon National University, Department of Biotechnology and Bioengineering, College of ACE, Kangwon National University |
| BackLink | https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003060238$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9kU1rHSEUhqWk0CTNH-hK6KYUJvVr1FmG0I9AoJCPtczoca7JvXqrziKb_vZ67wQKXRSRo4fnffXwnqGTmCIg9IGSS0qI-lIoY73qCBMdIYSKTr9Bp3RQsuOaypN2Zkx2miv2Dp2V8kSIUFrrU_T7vuaxwhygYJ8yrhvAEDdjtLCDWHHyeIw1dPbQyRi8B3vs7jeptO2asEIeC-D6sgfc4xA3YQo15YKXEuKMXV5mPIXoDhffeinifU4VQizv0Vs_bgtcvNZz9Pjt68P1j-725_eb66vbznKua6esEpIMg5pU76iTghLl3URGkFaQQVrt2pKDdB6Ip0IJxsBRQr3llE2Cn6PPq2_M3jzbYNIYjnVO5jmbq7uHG0PJwYrwBn9a4fbLX0ubz-xCsbDdjhHSUgynPZeMU9E39OM_6FNacmyjGDZwzoZeKNUotlI2p1IyeLPPYTfml_amOeRn1vxMy88c8zO6ifgqKg2OM-S_1v9R_QGx3J_Y |
| Cites_doi | 10.3390/scipharm87040029 10.1038/s41571-021-00470-8 10.1111/j.1742-1241.2006.01049.x 10.3390/ph13090245 10.1016/j.pharmthera.2005.07.003 10.1016/j.pharmthera.2014.10.003 10.1038/sj.ijir.3901577 10.1038/nrd3980 10.3390/cancers11010068 10.1517/13543780903485642 10.1038/nrd.2016.268 10.1016/j.coph.2011.10.003 10.18632/oncotarget.21837 10.3390/pharmaceutics14081707 10.1111/j.1743-6109.2008.01168.x 10.3389/fonc.2021.627229 10.1016/j.biomaterials.2021.120817 10.1039/D0CS00310G 10.1016/j.biopha.2020.111128 10.1016/j.nantod.2021.101119 10.1152/ajprenal.00042.2016 10.1186/s12935-022-02679-8 10.1038/sj.ijir.3901205 10.1016/j.coph.2011.08.004 10.1016/j.ejphar.2007.12.017 10.1080/14756366.2016.1250756 10.1016/j.phrs.2009.01.007 10.1007/s11255-015-1071-4 10.1016/j.sxmr.2015.10.004 10.1038/s41573-019-0033-4 10.1016/j.phrs.2010.06.008 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to The Korean Society for Biotechnology and Bioengineering and Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to The Korean Society for Biotechnology and Bioengineering and Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
| DBID | AAYXX CITATION 3V. 7QO 7QP 7T7 7WY 7WZ 7X7 7XB 87Z 88A 88I 8AO 8FD 8FE 8FG 8FH 8FI 8FJ 8FK 8FL ABJCF ABUWG AEUYN AFKRA ARAPS AZQEC BBNVY BENPR BEZIV BGLVJ BHPHI C1K CCPQU DWQXO FR3 FRNLG FYUFA F~G GHDGH GNUQQ HCIFZ K60 K6~ K9. L.- L6V LK8 M0C M0S M2P M7P M7S P5Z P62 P64 PHGZM PHGZT PKEHL PQBIZ PQBZA PQEST PQGLB PQQKQ PQUKI PTHSS Q9U 7S9 L.6 ACYCR |
| DOI | 10.1007/s12257-024-00014-8 |
| DatabaseName | CrossRef ProQuest Central (Corporate) Biotechnology Research Abstracts Calcium & Calcified Tissue Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) ABI/INFORM Collection ABI/INFORM Global (PDF only) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ABI/INFORM Collection Biology Database (Alumni Edition) Science Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ABI/INFORM Collection (Alumni) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Business Premium Collection Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Engineering Research Database Business Premium Collection (Alumni) Proquest Health Research Premium Collection ABI/INFORM Global (Corporate) Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Business Collection (Alumni Edition) ProQuest Business Collection ProQuest Health & Medical Complete (Alumni) ABI/INFORM Professional Advanced ProQuest Engineering Collection ProQuest Biological Science Collection ABI/INFORM Global Health & Medical Collection (Alumni) Science Database Biological Science Database Engineering Database Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest One Business ProQuest One Business (Alumni) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition Engineering Collection ProQuest Central Basic AGRICOLA AGRICOLA - Academic Korean Citation Index |
| DatabaseTitle | CrossRef ProQuest Business Collection (Alumni Edition) ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials SciTech Premium Collection ABI/INFORM Complete Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Biological Science Collection Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) Engineering Collection Advanced Technologies & Aerospace Collection Business Premium Collection ABI/INFORM Global Engineering Database ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Business Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ABI/INFORM Global (Corporate) ProQuest One Business Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ABI/INFORM Professional Advanced ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ABI/INFORM Complete (Alumni Edition) ABI/INFORM Global (Alumni Edition) ProQuest Central Basic ProQuest Science Journals ProQuest SciTech Collection Advanced Technologies & Aerospace Database Materials Science & Engineering Collection ProQuest One Business (Alumni) ProQuest Central (Alumni) Business Premium Collection (Alumni) AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | ProQuest Business Collection (Alumni Edition) AGRICOLA |
| Database_xml | – sequence: 1 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering Chemistry |
| EISSN | 1976-3816 |
| EndPage | 96 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_10409603 10_1007_s12257_024_00014_8 |
| GroupedDBID | --- -4Y -58 -5G -BR -EM -Y2 -~C .86 .UV .VR 06C 06D 0R~ 0VY 1N0 203 23N 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2WC 2~H 30V 3V. 4.4 406 408 40D 40E 53G 5GY 5VS 6NX 7WY 7X7 88A 88I 8AO 8FE 8FG 8FH 8FI 8FJ 8FL 8UJ 95- 95. 95~ 96X 9ZL A8Z AAAVM AABHQ AACDK AAHBH AAHNG AAIAL AAIKT AAJBT AAJKR AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABJCF ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACGOD ACHSB ACHXU ACIWK ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACSNA ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEUYN AEVLU AEXYK AFBBN AFGCZ AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARAPS ARCSS ARMRJ ASPBG AVWKF AXYYD AYJHY AZFZN AZQEC B-. BA0 BBNVY BBWZM BDATZ BENPR BEZIV BGLVJ BGNMA BHPHI BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 DWQXO E3Z EBD EBLON EBS EIOEI EJD ESBYG FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRNLG FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GROUPED_ABI_INFORM_COMPLETE H13 HCIFZ HF~ HG6 HMCUK HMJXF HRMNR HVGLF HZ~ I-F IJ- IKXTQ IWAJR IXC IXD I~X I~Z J-C J0Z JBSCW JZLTJ K60 K6~ KOV KVFHK L6V LK8 LLZTM M0C M0L M2P M4Y M7P M7S MA- ML0 MZR N2Q NDZJH NF0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OK1 P19 P2P P62 P9N PF0 PQBIZ PQBZA PQQKQ PROAC PT4 PT5 PTHSS Q2X QOK QOR QOS R89 R9I RHV RNI RNS ROL RPX RSV RZK S16 S1Z S26 S27 S28 S3B SAP SCG SCLPG SCM SDH SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW STPWE SZN T13 T16 TSG TUC TUS U2A UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W48 W4F WK8 YLTOR Z45 Z7U Z7V Z7W Z8Q ZMTXR ZZE ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT 7QO 7QP 7T7 7XB 8FD 8FK ABRTQ C1K FR3 K9. L.- P64 PKEHL PQEST PQGLB PQUKI Q9U 7S9 ESTFP L.6 PUEGO AABYN AAEOY AAFGU AAGCJ AAUCO AAYFA ABFGW ABKAS ABMYL ACBMV ACBRV ACBYP ACIGE ACIPQ ACTTH ACVWB ACWMK ACYCR ADMDM ADOXG AEEQQ AEFTE AESTI AEVTX AFNRJ AGGBP AIMYW AJDOV AJGSW AKQUC SQXTU UNUBA Z5O |
| ID | FETCH-LOGICAL-c338t-7c7460997b75d1d64107fdb0ae6c4096c8d8d8696dfe0f147422ed101fc312b43 |
| IEDL.DBID | U2A |
| ISSN | 1226-8372 |
| IngestDate | Fri Mar 15 19:04:08 EDT 2024 Mon Sep 08 06:27:04 EDT 2025 Fri Jul 25 19:01:13 EDT 2025 Tue Jul 01 02:05:45 EDT 2025 Fri Feb 21 02:41:50 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | PDE5 inhibitors HER2 Targeted delivery Recombinant fusion proteins Self-assemble |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c338t-7c7460997b75d1d64107fdb0ae6c4096c8d8d8696dfe0f147422ed101fc312b43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| PQID | 2933295477 |
| PQPubID | 54768 |
| PageCount | 12 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10409603 proquest_miscellaneous_3153623145 proquest_journals_2933295477 crossref_primary_10_1007_s12257_024_00014_8 springer_journals_10_1007_s12257_024_00014_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20240200 2024-02-00 20240201 2024-02 |
| PublicationDateYYYYMMDD | 2024-02-01 |
| PublicationDate_xml | – month: 2 year: 2024 text: 20240200 |
| PublicationDecade | 2020 |
| PublicationPlace | Seoul |
| PublicationPlace_xml | – name: Seoul – name: Dordrecht |
| PublicationTitle | Biotechnology and bioprocess engineering |
| PublicationTitleAbbrev | Biotechnol Bioproc E |
| PublicationYear | 2024 |
| Publisher | The Korean Society for Biotechnology and Bioengineering Springer Nature B.V 한국생물공학회 |
| Publisher_xml | – name: The Korean Society for Biotechnology and Bioengineering – name: Springer Nature B.V – name: 한국생물공학회 |
| References | Lugnier (CR4) 2006; 109 Shen, Johnson, Gobe (CR14) 2016; 311 Kutova, Guryev, Sokolova (CR26) 2019; 11 Savai, Pullamsetti, Banat (CR17) 2010; 19 Wright (CR8) 2006; 60 Walsh, Bargh, Dannheim (CR28) 2021; 50 Lim, Lee, Han (CR19) 2021; 273 Peak, Richman, Gur (CR11) 2016; 4 Das, Durrant, Salloum (CR7) 2015; 147 Levy, Horvath, Azevedo (CR1) 2011; 11 Schäfer, Fraccarollo, Werner (CR9) 2010; 62 Afsar, Ortiz, Covic (CR13) 2015; 47 Ahmed, Geethakumari, Biswas (CR2) 2021; 134 Cruz-Burgos, Losada-Garcia, Cruz- Hernández (CR18) 2021; 11 Malavige, Levy (CR16) 2009; 6 Marei, Cenciarelli, Hasan (CR27) 2022; 22 Drago, Modi, Chandarlapaty (CR31) 2021; 18 Francis, Corbin (CR15) 2011; 11 Zolot, Basu, Million (CR23) 2013; 12 Joubert, Beck, Dumontet (CR29) 2020; 13 Li, Sun, Li (CR10) 2009; 59 Corbin (CR3) 2004; 16 de Oliveira, Lescano, De Nucci (CR20) 2019; 87 Beck, Goetsch, Dumontet (CR30) 2017; 16 Baillie, Tejeda, Kelly (CR5) 2019; 18 Sandner, Hütter, Tinel (CR12) 2007; 19 Delfi, Sartorius, Ashrafizadeh (CR25) 2021; 38 Barone, Giordano, Bonofiglio (CR22) 2017; 8 Han, Lim, Blackburn (CR24) 2022; 14 Kayık, Tüzün, Durdagi (CR21) 2017; 32 Santos-Silva, Cairrão, Morgado (CR6) 2008; 582 M Li (14_CR10) 2009; 59 GS Baillie (14_CR5) 2019; 18 I Levy (14_CR1) 2011; 11 KS Lim (14_CR19) 2021; 273 RS Zolot (14_CR23) 2013; 12 LS Malavige (14_CR16) 2009; 6 C Lugnier (14_CR4) 2006; 109 B Afsar (14_CR13) 2015; 47 A Beck (14_CR30) 2017; 16 N Joubert (14_CR29) 2020; 13 S Han (14_CR24) 2022; 14 OM Kutova (14_CR26) 2019; 11 JZ Drago (14_CR31) 2021; 18 HE Marei (14_CR27) 2022; 22 P Sandner (14_CR12) 2007; 19 G Kayık (14_CR21) 2017; 32 PJ Wright (14_CR8) 2006; 60 SH Francis (14_CR15) 2011; 11 AJ Santos-Silva (14_CR6) 2008; 582 A Schäfer (14_CR9) 2010; 62 TC Peak (14_CR11) 2016; 4 JD Corbin (14_CR3) 2004; 16 M Delfi (14_CR25) 2021; 38 WS Ahmed (14_CR2) 2021; 134 K Shen (14_CR14) 2016; 311 IP de Oliveira (14_CR20) 2019; 87 M Cruz-Burgos (14_CR18) 2021; 11 A Das (14_CR7) 2015; 147 R Savai (14_CR17) 2010; 19 I Barone (14_CR22) 2017; 8 SJ Walsh (14_CR28) 2021; 50 |
| References_xml | – volume: 87 start-page: 29 year: 2019 ident: CR20 article-title: In silico mapping of essential residues in the catalytic domain of PDE5 responsible for stabilization of its commercial inhibitors publication-title: Sci Pharm doi: 10.3390/scipharm87040029 – volume: 18 start-page: 327 year: 2021 end-page: 344 ident: CR31 article-title: Unlocking the potential of antibody-drug conjugates for cancer therapy publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-021-00470-8 – volume: 60 start-page: 967 year: 2006 end-page: 975 ident: CR8 article-title: Comparison of phosphodiesterase type 5 (PDE5) inhibitors publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2006.01049.x – volume: 13 start-page: 245 year: 2020 ident: CR29 article-title: Antibody-drug conjugates: the last decade publication-title: Pharmaceuticals (Basel) doi: 10.3390/ph13090245 – volume: 109 start-page: 366 year: 2006 end-page: 398 ident: CR4 article-title: Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2005.07.003 – volume: 147 start-page: 12 year: 2015 end-page: 21 ident: CR7 article-title: PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2014.10.003 – volume: 19 start-page: 533 year: 2007 end-page: 543 ident: CR12 article-title: PDE5 inhibitors beyond erectile dysfunction publication-title: Int J Impot Res doi: 10.1038/sj.ijir.3901577 – volume: 12 start-page: 259 year: 2013 end-page: 260 ident: CR23 article-title: Antibody-drug conjugates publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3980 – volume: 11 start-page: 68 year: 2019 ident: CR26 article-title: Targeted delivery to tumors: multidirectional strategies to improve treatment efficiency publication-title: Cancers (Basel) doi: 10.3390/cancers11010068 – volume: 19 start-page: 117 year: 2010 end-page: 131 ident: CR17 article-title: Targeting cancer with phosphodiesterase inhibitors publication-title: Expert Opin Investig Drugs doi: 10.1517/13543780903485642 – volume: 16 start-page: 315 year: 2017 end-page: 337 ident: CR30 article-title: Strategies and challenges for the next generation of antibody-drug conjugates publication-title: Nat Rev Drug Discov doi: 10.1038/nrd.2016.268 – volume: 11 start-page: 689 year: 2011 end-page: 697 ident: CR1 article-title: Phosphodiesterase function and endocrine cells: links to human disease and roles in tumor development and treatment publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2011.10.003 – volume: 8 start-page: 99179 year: 2017 end-page: 99202 ident: CR22 article-title: Phosphodiesterase type 5 and cancers: progress and challenges publication-title: Oncotarget doi: 10.18632/oncotarget.21837 – volume: 14 start-page: 1707 year: 2022 ident: CR24 article-title: The potential of topoisomerase inhibitor-based antibody-drug conjugates publication-title: Pharmaceutics doi: 10.3390/pharmaceutics14081707 – volume: 6 start-page: 1232 year: 2009 end-page: 1247 ident: CR16 article-title: Erectile dysfunction in diabetes mellitus publication-title: J Sex Med doi: 10.1111/j.1743-6109.2008.01168.x – volume: 11 year: 2021 ident: CR18 article-title: New approaches in oncology for repositioning drugs: the case of PDE5 inhibitor sildenafil publication-title: Front Oncol doi: 10.3389/fonc.2021.627229 – volume: 273 year: 2021 ident: CR19 article-title: Targeted delivery of heat shock protein 90 inhibitors prevents growth of HER2-positive tumor publication-title: Biomaterials doi: 10.1016/j.biomaterials.2021.120817 – volume: 50 start-page: 1305 year: 2021 end-page: 1353 ident: CR28 article-title: Site-selective modification strategies in antibody-drug conjugates publication-title: Chem Soc Rev doi: 10.1039/D0CS00310G – volume: 134 year: 2021 ident: CR2 article-title: Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2020.111128 – volume: 38 year: 2021 ident: CR25 article-title: Self-assembled peptide and protein nanostructures for anti-cancer therapy: targeted delivery, stimuli-responsive devices and immunotherapy publication-title: Nano Today doi: 10.1016/j.nantod.2021.101119 – volume: 311 start-page: F671 year: 2016 end-page: F681 ident: CR14 article-title: The role of cGMP and its signaling pathways in kidney disease publication-title: Am J Physiol Renal Physiol doi: 10.1152/ajprenal.00042.2016 – volume: 22 start-page: 255 year: 2022 ident: CR27 article-title: Potential of antibody-drug conjugates (ADCs) for cancer therapy publication-title: Cancer Cell Int doi: 10.1186/s12935-022-02679-8 – volume: 16 start-page: S4 issue: Suppl 1 year: 2004 end-page: S7 ident: CR3 article-title: Mechanisms of action of PDE5 inhibition in erectile dysfunction publication-title: Int J Impot Res doi: 10.1038/sj.ijir.3901205 – volume: 11 start-page: 683 year: 2011 end-page: 688 ident: CR15 article-title: PDE5 inhibitors: targeting erectile dysfunction in diabetics publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2011.08.004 – volume: 582 start-page: 102 year: 2008 end-page: 109 ident: CR6 article-title: PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2007.12.017 – volume: 32 start-page: 311 year: 2017 end-page: 330 ident: CR21 article-title: Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development publication-title: J Enzyme Inhib Med Chem doi: 10.1080/14756366.2016.1250756 – volume: 59 start-page: 312 year: 2009 end-page: 318 ident: CR10 article-title: Inhibition of cGMP phosphodiesterase 5 suppresses serotonin signalling in pulmonary artery smooth muscles cells publication-title: Pharmacol Res doi: 10.1016/j.phrs.2009.01.007 – volume: 47 start-page: 1521 year: 2015 end-page: 1528 ident: CR13 article-title: Phosphodiesterase type 5 inhibitors and kidney disease publication-title: Int Urol Nephrol doi: 10.1007/s11255-015-1071-4 – volume: 4 start-page: 74 year: 2016 end-page: 84 ident: CR11 article-title: The role of PDE5 inhibitors and the NO/cGMP pathway in cancer publication-title: Sex Med Rev doi: 10.1016/j.sxmr.2015.10.004 – volume: 18 start-page: 770 year: 2019 end-page: 796 ident: CR5 article-title: Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-019-0033-4 – volume: 62 start-page: 432 year: 2010 end-page: 438 ident: CR9 article-title: Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure publication-title: Pharmacol Res doi: 10.1016/j.phrs.2010.06.008 – volume: 14 start-page: 1707 year: 2022 ident: 14_CR24 publication-title: Pharmaceutics doi: 10.3390/pharmaceutics14081707 – volume: 13 start-page: 245 year: 2020 ident: 14_CR29 publication-title: Pharmaceuticals (Basel) doi: 10.3390/ph13090245 – volume: 11 start-page: 68 year: 2019 ident: 14_CR26 publication-title: Cancers (Basel) doi: 10.3390/cancers11010068 – volume: 19 start-page: 117 year: 2010 ident: 14_CR17 publication-title: Expert Opin Investig Drugs doi: 10.1517/13543780903485642 – volume: 12 start-page: 259 year: 2013 ident: 14_CR23 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd3980 – volume: 273 year: 2021 ident: 14_CR19 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2021.120817 – volume: 32 start-page: 311 year: 2017 ident: 14_CR21 publication-title: J Enzyme Inhib Med Chem doi: 10.1080/14756366.2016.1250756 – volume: 8 start-page: 99179 year: 2017 ident: 14_CR22 publication-title: Oncotarget doi: 10.18632/oncotarget.21837 – volume: 38 year: 2021 ident: 14_CR25 publication-title: Nano Today doi: 10.1016/j.nantod.2021.101119 – volume: 311 start-page: F671 year: 2016 ident: 14_CR14 publication-title: Am J Physiol Renal Physiol doi: 10.1152/ajprenal.00042.2016 – volume: 147 start-page: 12 year: 2015 ident: 14_CR7 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2014.10.003 – volume: 11 year: 2021 ident: 14_CR18 publication-title: Front Oncol doi: 10.3389/fonc.2021.627229 – volume: 109 start-page: 366 year: 2006 ident: 14_CR4 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2005.07.003 – volume: 18 start-page: 770 year: 2019 ident: 14_CR5 publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-019-0033-4 – volume: 582 start-page: 102 year: 2008 ident: 14_CR6 publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2007.12.017 – volume: 60 start-page: 967 year: 2006 ident: 14_CR8 publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2006.01049.x – volume: 47 start-page: 1521 year: 2015 ident: 14_CR13 publication-title: Int Urol Nephrol doi: 10.1007/s11255-015-1071-4 – volume: 22 start-page: 255 year: 2022 ident: 14_CR27 publication-title: Cancer Cell Int doi: 10.1186/s12935-022-02679-8 – volume: 6 start-page: 1232 year: 2009 ident: 14_CR16 publication-title: J Sex Med doi: 10.1111/j.1743-6109.2008.01168.x – volume: 16 start-page: 315 year: 2017 ident: 14_CR30 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd.2016.268 – volume: 87 start-page: 29 year: 2019 ident: 14_CR20 publication-title: Sci Pharm doi: 10.3390/scipharm87040029 – volume: 134 year: 2021 ident: 14_CR2 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2020.111128 – volume: 16 start-page: S4 issue: Suppl 1 year: 2004 ident: 14_CR3 publication-title: Int J Impot Res doi: 10.1038/sj.ijir.3901205 – volume: 4 start-page: 74 year: 2016 ident: 14_CR11 publication-title: Sex Med Rev doi: 10.1016/j.sxmr.2015.10.004 – volume: 18 start-page: 327 year: 2021 ident: 14_CR31 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-021-00470-8 – volume: 11 start-page: 689 year: 2011 ident: 14_CR1 publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2011.10.003 – volume: 19 start-page: 533 year: 2007 ident: 14_CR12 publication-title: Int J Impot Res doi: 10.1038/sj.ijir.3901577 – volume: 59 start-page: 312 year: 2009 ident: 14_CR10 publication-title: Pharmacol Res doi: 10.1016/j.phrs.2009.01.007 – volume: 11 start-page: 683 year: 2011 ident: 14_CR15 publication-title: Curr Opin Pharmacol doi: 10.1016/j.coph.2011.08.004 – volume: 62 start-page: 432 year: 2010 ident: 14_CR9 publication-title: Pharmacol Res doi: 10.1016/j.phrs.2010.06.008 – volume: 50 start-page: 1305 year: 2021 ident: 14_CR28 publication-title: Chem Soc Rev doi: 10.1039/D0CS00310G |
| SSID | ssj0047888 |
| Score | 2.3348174 |
| Snippet | Drug repurposing is a rapidly growing for the development of new therapeutic agents. Among them, phosphodiesterase-5 (PDE5) inhibitors, which show excellent... |
| SourceID | nrf proquest crossref springer |
| SourceType | Open Website Aggregation Database Index Database Publisher |
| StartPage | 85 |
| SubjectTerms | Antibodies Anticancer properties antineoplastic activity Antineoplastic drugs Binding Biotechnology Cancer Chemistry Chemistry and Materials Science domain drugs ErbB-2 protein Erectile dysfunction Fusion protein Industrial and Production Engineering Inhibitors Pharmacology Phosphodiesterase Proteins recombinant fusion proteins Research Paper therapeutics 생물공학 |
| SummonAdditionalLinks | – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEB_68aIPpa2K0Vq26Jsu5mOzuTwVEc9aqE8W-rbs510oJGdy99q_3Zm9xLOCEkJgQz6Ymd35zecCvJNC14ImkvMh5aLMNdd5pnkdhKsNpS1Kqka--S6vbsX1XXk3OtyGMa1yWhPjQu06Sz7yj6iWCopJVdXl6ienXaMoujpuobEPhxlqGpLz2fzrtBJTZ_hYCocQg6Mhlo9FM9vSORTkiqOG4tFM4LNHimm_7cMjzPlXmDRqn_kxHI2wkX3a8vkE9nx7Ck__aCb4DB6mRrN-YIhEGSI75tslcZU8gKwLDKnYcEsjPdsmctDoatkNeFI6IZUjD56RX5aVrGmXjWloOx5G6fEL5vrNgpkmFsKwsCFHG4uNHpp2eA638y8_Pl_xcXcFbtEsXfPKVkJS3aypSpc5KdAQDM6k2kuLRp-0M4eHrKULPg2ZQBs69w5ncLBFlhtRvICDtmv9S2BVHmrvSxsM2jfBldrqgMTXFrFblRqbwPuJtGq1baKhdu2SiREKGRHj4ELNEniL1Ff3tlHU-5qui07d9woR_jd8iH4uLRI4m7ijxmk3qJ2QJHDx-zZOGIqC6NZ3m0EVuMYj5stEmcCHiau7V_z7v179_4uv4UkexYlSXc7gYN1v_BsELGtzHqXyFx7E56k priority: 102 providerName: ProQuest |
| Title | Strategies for the enhancement of anti-cancer effect of phosphodiesterase type 5 inhibitors using drug binding fusion proteins |
| URI | https://link.springer.com/article/10.1007/s12257-024-00014-8 https://www.proquest.com/docview/2933295477 https://www.proquest.com/docview/3153623145 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003060238 |
| Volume | 29 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Biotechnology and Bioprocess Engineering, 2024, 29(1), , pp.85-96 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwEB7R3QNwQLCANrBURnADS3k4dnNsV-0uICqEqFROVuJHG62UrJL2ym9nJk0oi-CAosSSk1iWPz--8TwM8FaKPBM0kKzzIRdpnPM8jnKeeWGzgswWJXkjf17K65X4uE7XvVNYO1i7DyrJbqY-Orth11Mc1xTeEXs-GcFpirI7DcdVPB3mX4oH3znAIbHgKH7FvavM38u4sxyNqsbfYZp_KEe7NWfxGB71ZJFND-g-gXuuOoP7l8MZbWfw8Ldwgk_hxxBq1rUMuShDbsdctSVcaQ-Q1Z5hO5bcUE7DDqYclHu7rVu8yaCQHJJbx2hnlqWsrLZlUdKBPIwM5DfMNvsNK8rOFYb5PW21sS7UQ1m1z2C1mH-7vOb9-QrcoGC648ooIclztlCpjawUKAp6W4S5kwbFPmkmFi-ZSetd6COBUnTsLI5hb5IoLkTyHE6qunLnwFTsM-dS4wuUcLxNc5N7BCI3yN5UWJgA3g3NrG8PYTT0MWAygaIRlE4TLvQkgDeIhL4xpabo15Ruan3TaOT4H_AnqlyYBHAxIKX7gddqZC8JqS6VCuD1r9eICulB8srV-1YnOMsj64tEGsD7AeFjEf-u14v_-_wlPIi7rkbGLxdwsmv27hVSmF0xhpFaK3xOFldjOJ0uZrMlpVffP80xnc2XX76Ou179E6l17rk |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB616QE4VDyFaYFFwAlW2Ou1HR8Q4tEqoW2EUCv1ttj7SKxKdrATIS78JH4jM34QigS3KooirRXb2pnZmW9nvlmAZ7HMUkmGZKzzuYxExjMRZDx10qQ5lS3GxEY-mcWTM_nxPDrfgp8DF4bKKoc1sV2oTaVpj_wVuqWQclJJ8mb5ldOpUZRdHY7Q6NTiyH7_hpCteT39gPJ9LsThwen7Ce9PFeAa4diKJzqRMfFF8yQygYklAiBncj-zsUawE-uxwU-cxsZZ3wUSsaOwBjXX6TAQuQzxvtuwI4nROoKddwezT5-HtZ960bfkOwxqOEI_0dN0OrIemk7C0SfyFpjw8SVXuF3W7lKU-1ditvV3hzdhtw9U2dtOs27Bli1vw40_2hfegR9Da1vbMIx9GcaSzJYL0iPac2SVYyi3gmsaqVlXOkKjy0XV4JcKGIkA3VhGO8EsYkW5KPKCDgBiVJA_Z6Zez1letNQb5ta0tcfa1hJF2dyFsyuZ-XswKqvS3geWCJdaG2mXI6JyJsp05nDyM43RYuLn2oMXw9SqZde2Q20aNJMgFAqizbxLNfbgKc6-utCFom7b9Duv1EWtEFNM8U_0cn7owf4gHdUbeqM2aunBk9-X0UQp75KVtlo3KkSvglFmICMPXg5S3dzi3-_14P9PfAzXJqcnx-p4Ojvag-uiVS0qtNmH0ape24cYLq3yR72OMvhy1WbxC8OMJSM |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Li9RAEC52VxA9iE-MrtqinrTZPDrdk4OIuA47ri4eXJhbm_RjJiwkYzKDePGH-eusymPHFfS2hBBIyIOuqtT3dT0a4LkUeSbIkKzzIRdpnPM8jnKeeWGzgtIWJVUjfzqRR6fiwzyd78CvsRaG0irHf2L3o7a1oTnyA3RLCcWklDrwQ1rE58Ppm9U3TitIUaR1XE6jV5Fj9-M70rf29ewQZf0ijqfvv7w74sMKA9wgNVtzZZSQVDtaqNRGVgokQ94WYe6kQeIjzcTiJjNpvQt9JJBHxs6iFnuTRHEhEnzuLlxRCaIqtCU1Pyd71JW-K8NDeMORBMZDwU5ftodGpDh6R95RFD654BR3q8ZfwLt_hWg7zze9CTcGyMre9jp2C3ZcdRuu_9HI8A78HJvcupYhCmaIKpmrlqRRNPvIas9QgiU3dKZhfRIJnV0t6xZ3SmWkUujWMZoTZikrq2VZlLQUEKPU_AWzzWbBirIrwmF-Q5N8rGsyUVbtXTi9lHG_B3tVXbn7wFTsM-dS4wvkVt6muck9Dn5uEDeqsDABvByHVq_6Bh5626qZBKFREF0MXuhJAM9w9PWZKTX13abjotZnjUZ2McOb6OPCJID9UTp6MPlWbxU0gKfnl9FYKQKTV67etDpB_4J4MxJpAK9GqW4f8e_vevD_Nz6Bq2gM-uPs5PghXIs7zaKMm33YWzcb9whx07p43Ckog6-XbRG_ATueJ-o |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Strategies+for+the+enhancement+of+anti-cancer+effect+of+phosphodiesterase+type+5+inhibitors+using+drug+binding+fusion+proteins&rft.jtitle=Biotechnology+and+bioprocess+engineering&rft.au=Kim%2C+Hongbin&rft.au=Keum%2C+Chang+Yeop&rft.au=Lim%2C+Su+Yeon&rft.au=Lim%2C+Kwang+Suk&rft.date=2024-02-01&rft.issn=1226-8372&rft.eissn=1976-3816&rft.volume=29&rft.issue=1&rft.spage=85&rft.epage=96&rft_id=info:doi/10.1007%2Fs12257-024-00014-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1007_s12257_024_00014_8 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1226-8372&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1226-8372&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1226-8372&client=summon |